In stage IIIB‐IV, NSCLC patients (n = 40) treated with αPD‐(L)1, higher diversity within the circulating PD‐1+ CD8+ T‐cell fraction prior to the start of therapy was associated with longer mPFS (6.4 vs. 2.5 months) and mOS (not reached at 25 vs. 10.1 months).56 The gene discussed is CD8A; the disease is non-small cell lung carcinoma.